Mavyret is an oral medication used to treat chronic hepatitis C virus (HCV) infection [1]. It is available in tablet form, and while there are no currently available pellet formulations, the medication's active ingredients are glecaprevir and pibrentasvir [2].
What is Mavyret used for?
Mavyret is prescribed for adults with genotype 1, 2, 3, 4, 5, or 6 chronic hepatitis C infection without cirrhosis or with mild cirrhosis. It is also used in patients with moderate to severe cirrhosis who have not been successfully treated with other HCV therapies [1].
How does Mavyret work?
The active components of Mavyret, glecaprevir and pibrentasvir, work together to inhibit two proteins essential for the hepatitis C virus's life cycle [2]. Glecaprevir is an NS3/4A protease inhibitor, and pibrentasvir is an NS5A inhibitor [1]. By blocking these targets, Mavyret prevents the virus from replicating [2].
How is Mavyret administered?
Mavyret is taken orally as three oral tablets once daily with food [1].
When does Mavyret's patent expire?
The patent landscape for Mavyret is complex and involves multiple patents protecting its active ingredients and formulations. Information on specific patent expiry dates and any ongoing patent litigation can be found through resources like DrugPatentWatch.com [3].
Who manufactures Mavyret?
Mavyret is manufactured by AbbVie Inc. [4].